The setup heading into ASML's October 14 earnings is mixed-to-cautiously-favorable: the stock has staged a sharp +16.6% recovery off its September 14 low of $1,572.84 and is forming a bullish converging wedge, but it sits essentially at 100-day resistance with a neutral-to-cautious near-term options signal. Analyst estimate revisions are decisively one-sided — 26 upward vs. just 1 downward in the past 30 days — which suggests institutional conviction is building heading into the print.
The Setup: A Sharp Recovery Meets a Key Technical Ceiling
ASML closed at $1,834.10 on October 6, sitting just 0.1% below its 100-day resistance of $1,835.46 — a level that has capped the stock for much of the recent trading range. The 20-day uptrend is the clearest bullish signal on the chart: ASML has gained +6.05% over the past 20 sessions, with defined 20-day support at $1,791.25 and resistance at $1,873.50, the latter marking the October 2 intraday high.
The scanner has flagged a Converging Wedge (Bullish) pattern with pattern support at $1,700.88 and resistance at $1,873.50. This structure typically resolves with a directional break, and with earnings six days away, the catalyst is obvious. Notably, ASML's 5-day trend has gone sideways and is near support, suggesting the stock is coiling rather than distributing ahead of the event. The 20-day SMA sits at $1,733.37 and the 50-day at $1,727.54 — both well below current price — reinforcing the underlying recovery momentum.
On a longer timeframe, ASML is +15.75% above its 100-day trendline base, positioned above the mean on a standard-deviation basis (a bullish signal), and carries a "strong" relative strength reading on the 100-day frame. The stock is trading at a market cap of approximately $714 billion, making it one of the largest technology companies in the world by that measure.
What the Options Market Says
Options flow carries an overall score of 66/100, flagged as an accumulation signal with a bullish MACD reading and an RSI of 61.9 — neither overbought nor oversold. The flow signal leans constructively, consistent with positioning ahead of a potential positive catalyst.
Dealer positioning places the call wall at $2,000 (17,362 contracts in open interest) and the put wall at $1,500 (16,448 contracts). This wide corridor — spanning $500, or roughly 27% of current price — reflects the inherent uncertainty around a major earnings event for a high-priced, widely-followed name. The $2,000 call wall represents meaningful upside of approximately 9% from current levels, while the $1,500 put wall sits about 18% below, consistent with the protection buyers are pricing in around a volatile report.
In terms of pre-earnings positioning, call open interest has been building at the $2,300 strike (+3,097 contracts), suggesting some traders are positioning for an outsized upside scenario. On the put side, notable builds appear at $1,650 (+5,015 contracts) and $1,290 (+3,044 contracts) — the former representing a plausible near-term downside target if earnings disappoint, the latter a tail-risk hedge level.
The overall options signal is classified NEUTRAL_BEARISH with low confidence, and the put/call ratio sits at parity (50/50). Despite the constructive flow score, the pre-earnings put build at $1,650 is notable — that level would represent a ~10% drawdown from current price and suggests some institutional players are actively hedging against a negative surprise, not merely writing protection as routine book management.
Fundamentals & Estimates: A High Bar, Convincingly Cleared — So Far
The consensus estimate for the quarter ending October 14 calls for EPS of $10.65 (range: $8.65–$11.50 across 16 analysts), representing +93.9% growth year-over-year against $5.49 earned in the year-ago quarter. Revenue consensus sits at ~$11.69 billion (range: $10.52B–$12.21B), implying +55.5% year-over-year growth from the $7.52 billion posted a year ago. That is a steep bar — but one that analysts have been steadily raising.
The full-year 2026 EPS consensus stands at $38.35 (+55.2% vs. 2025's $24.71), with 2027 estimates at $51.92 (+35.4% further growth). Annual revenue is expected to reach $42.88 billion for 2026 and $54.61 billion in 2027. These numbers underscore the extraordinary growth trajectory the market is ascribing to ASML's EUV and high-NA EUV installed base expansion.
On valuation, the stock trades at a forward P/E of 28.9x (based on 2026 estimates) and a PEG ratio of 1.58 — not cheap, but defensible given the monopoly moat. The trailing P/E of 60.4x reflects the earnings ramp underway. Profit margin stands at 30.1% and return on equity at 53.9%. The Wall Street consensus price target is $2,096 (mean) to $2,137 (median), implying +14.3% upside from current levels. Of 42 analysts covering the stock, 38 rate it Buy or Strong Buy, 3 Hold, and just 1 Sell.
The revision momentum is a clear positive signal: 26 upward EPS revisions vs. 1 downward in the past 30 days. The current-year EPS estimate has moved from $31.86 ninety days ago to $38.35 today — a +20.4% upward revision in three months. Analysts are not just maintaining their models; they are meaningfully raising the bar.
From a supply chain standpoint, ASML holds a bottleneck score of 10/10 — the highest possible — reflecting its unique monopoly position as the sole producer of Extreme Ultraviolet (EUV) lithography machines used by every leading-edge chipmaker. TSMC, Intel, Samsung, and Micron cannot manufacture advanced chips without ASML equipment. That structural irreplaceability is the foundation of both the premium valuation and the analyst conviction.
Key Levels to Watch
| Level | Price | Significance |
|---|---|---|
| Call Wall (dealer resistance) | $2,000 | Major upside magnet / likely containment on a beat |
| Pattern Resistance / 20-day high | $1,873.50 | First resistance; must clear on a gap-up for follow-through |
| 100-Day Resistance | $1,835.46 | Current ceiling; stock pressing against it pre-earnings |
| Current Price | $1,834.10 | Last close (Oct 6) |
| 20-Day Support | $1,791.25 | First support on a mild post-earnings pullback |
| Put Build / Downside Target | $1,650 | Significant put open interest; key level on a miss |
| Pattern Support (Wedge base) | $1,700.88 | Structural support; break here would negate bullish wedge |
| Put Wall (dealer support) | $1,500 | Extreme downside floor; tail-risk scenario only |
Bottom Line
ASML enters its October 14 print with a credible bull case: a recovering price structure, a monopoly-grade supply chain position, and the strongest analyst revision momentum in the sector (26 upgrades vs. 1 downgrade in 30 days). The $10.65 EPS consensus and $11.69 billion revenue bar are high, but three months of upward revisions suggest analysts believe management's guidance trajectory is intact. If ASML beats and guides in-line or higher, $1,873.50 is the first resistance to clear, with the dealer call wall at $2,000 as the logical target for a strong beat-and-raise scenario.
The key downside scenario is a revenue miss driven by order softness or customer push-outs from TSMC or Samsung. The put build at $1,650 signals that hedgers are actively protecting against a ~10% drawdown. A miss combined with cautious forward guidance — particularly around high-NA EUV system deliveries — could quickly test the $1,700.88 wedge base. A break of that level would flip the technical picture from bullish consolidation to distribution.
For investors, the setup is best described as a high-reward, high-risk event with a slight bullish tilt. The converging wedge, recovering momentum, and overwhelming analyst conviction (38 of 42 analysts bullish, mean target $2,096) support a constructive bias — but the wide $1,500–$2,000 dealer corridor and balanced put/call positioning argue against leveraged directional bets without defined risk. If you hold ASML into earnings, $1,791 is the line in the sand; a post-earnings close above that level keeps the bullish structure intact regardless of the initial reaction.
This article was generated by Tradestie Alpha Assistant using live market data (investment scores, options positioning, trendlines, and fundamentals) and reviewed before publication. It is for informational purposes only and is not financial advice. Do your own research before making investment decisions.